Posts by David N. Louis, MD
-
Developing New Assays for Novel COVID-19: Q&A with David Louis, MD
David Louis, MD, pathologist-in-chief at Massachusetts General Hospital, explains how COVID-19 assays are being rapidly developed and what Mass General is doing to alleviate the scarcity of tests.
Biography
Dr. Louis is Benjamin Castleman Professor of Pathology at Harvard Medical School (HMS) and Pathologist-in-Chief at Massachusetts General Hospital (MGH). Under Dr. Louis, the department has become a national leader in molecular diagnostics and pathology informatics, leading to the novel field of computational pathology. Dr. Louis' research focuses on brain tumors and the application of molecular diagnostics to glioma classification, with over 300 original articles (h-index = 108). His laboratory was first to demonstrate that molecular approaches could subdivide malignant gliomas biologically and predict the response of malignant gliomas to specific therapies. This work has contributed to worldwide adoption of molecular testing for the management of glioma patients. Dr. Louis has received prestigious awards for his work, including the 2008 Zülch Prize of the Max Planck Society, and has been primary editor for both the 2007 and the 2016 WHO Classification of Tumours of the Central Nervous System. He is chair of the CNS committee for the International Collaboration on Cancer Reporting and is founder of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Dr. Louis was co-chair of the NIH Brain Tumor Progress Review Group and founding chair of the Cancer Biomarkers Study Section at NIH. Dr. Louis recently served as chair of the HMS Pathology Executive Committee, which governs HMS Pathology, and as chair of the MGH Executive Committee on Research, which oversees an approximately $900M research enterprise. Dr. Louis is currently Executive Sponsor of the MGH Center for Innovation in Digital Health.